

CLAIMS

1. A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to
5 said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof.
2. A method for the production of an antiangiogenic and/or vascular permeability
10 reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, and before, after or simultaneously with an effective amount of ionising radiation.
15
3. A method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof.
20
4. A method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, and before, after or
25 simultaneously with an effective amount of ionising radiation.
5. A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with
30 an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof.
6. A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of

AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, and before, after or simultaneously with an effective amount of ionising radiation.

5 7. A pharmaceutical composition which comprises AZD2171 or a pharmaceutically acceptable salt thereof, and ZD6126 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

8. A kit comprising AZD2171 or a pharmaceutically acceptable salt thereof, and
10 ZD6126 or a pharmaceutically acceptable salt thereof.

9. Use of AZD2171 or a pharmaceutically acceptable salt thereof and ZD6126 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a
15 warm-blooded animal such as a human.

10. Use of AZD2171 or a pharmaceutically acceptable salt thereof and ZD6126 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a
20 warm-blooded animal such as a human which is being treated with ionising radiation.

11. Use of AZD2171 or a pharmaceutically acceptable salt thereof and ZD6126 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human.

25

12. Use of AZD2171 or a pharmaceutically acceptable salt thereof and ZD6126 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.

30

13. Use of AZD2171 or a pharmaceutically acceptable salt thereof and ZD6126 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human.

- 22 -

14. Use of AZD2171 or a pharmaceutically acceptable salt thereof and ZD6126 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human which is being treated with ionising radiation.